ArticleThe Journal of clinical investigation2025

Chemotaxis overrides the killing response in alloreactive CTLs, providing vascular immune privilege during cellular rejection.

Thomas Barba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.